Progress and Perspective in the Treatment of Lung Cancer

ISBN-13: 9783540625483 / Angielski / Twarda / 1999 / 280 str.

P. Van Houtte; J. Klastersky; P. Rocmans

Opis

Lung cancer is not a single disease process but is a group of biologically variable diseases. Therefore, accurate and complete diagnosis along with complete workup of the patient prior to decision-making in treatment is essential to devise the most appropriate treatment strategy. In North America adenocarcinoma of the lung now accounts for about 40% of all lung cancers and stage for stage these tumors have a poorer prognosis than squamous cell cancers of the lung. Many prognostic indicators have been identified such as genetic markers and neuroen docrine differentiation, which have important roles to play in identifying the patients who would benefit most from active treatment. Screening and early detection have been thought to be sine qua non in early diagnosis of lung cancer. However, a number of controlled trials assessing the value of annual screening for lung cancer have demonstrated in some studies that chest X-rays and/or cytology screening may improve stage distribution, resectability, survival, and fatality but has not shown an impact on disease-specific mortality rates. The Mayo Clinic lung project compar ing quarterly chest X-rays and sputum cytology with routine care in more than 10 000 male smokers indicated that 5-year survival following treatment in the screened patients was better than rates in contemporary clinical practice. However, arguments have been ad vanced as to factors that might have biased the clinical benefits. Other trials are currently under way to deal with this issue along with new molecular markers that may enhance sputum sensitivity."

Spis treści

1 Prognostic Factors: From Clinical Parameters to New Biological Markers J.B. Sorensen and K. Osterlind 2 Radiological Evaluation of Intrathoracic Extension and Resectability of Non-Small Cell Lung Cancer J.A. Hanson and P. Armstrong 3 Positron Emission Tomography: A New Toolin Diagnosing Staging and Treatment of Lung Cancer C. Schiepers 4 Exclusive Surgery for Stage III Disease: Is it Still Ethical P. Rocmans 5 Induction Chemotherapy With or Without Radiotherapy Followed by Surgery in Non-Small Cell Lung Cancer K.S. Albain 6 Adjuvant Treatment in Non-Small Cell Cancer S.S. Leong, C.M.S. Rocha Lima, and M.R. Green 7 Induction or Concurrent Chemotherapy and Radiotherapy for Locally Advanced Non-Small Cell Lunger Cancer R. Komaki and J.D. Cox 8 Exclusive Radiotherapy for NSC Lung Cancer H.-P. Heilmann, F. Wuerschmidt, and H. Buenemann 9 3D Conformal Radiotherapy in Treatment of Bronchogenic Carcinoma B. Emami 10 Endoluminal Brachytherapy: A Curative Modality? E. Lartigau, H. Marsiglia, and P. Baldeyrou 11 Integration of Radiotherapy and Chemotherapy for Small Cell Lung Cancer H. Wagner 12 The Role of PCI: Benefits and Late Effects A. Gregor and A. Cull 13 Fractionation as a Biological Dose Modifier M.I. Saunders 14 Biochemical and Biological Dose Modifyers for Irradiation of Lunger Cancers R.O. Mirimanoff 15 Intraoperative Radiotherapy for Lung Cancer F.A. Calvo, J.J. Aristu, M. Moreno, M. Santos, and S.A. Fisher 16 Should all Stage IV be Treated Palliatively? F. Cappuzzo, A. Zappala, and T. Le Chevalier Thierry 17 Intensive Therapy of Small Cell Lunger Cancer: A Review of Recently Published Data J. Klastersky and D. Derriendt 18 Best Supportive Care or Chemotherapy for Stage IV Non-Small Cell Lung Cancer J.P. Sculier, T. Berghmans, C. Castaigne, Y. Lalami, S. Luce, C. Sotiriou, P. Vermylen,, and M. Paesans 19 Do we have the Real Tool to Evaluate Toxicity? The Lent Soma Approach F. Mornex, J.J. Pavy, and J. Denekamp 20 The Issue of Treatment Indication and Clinical Target Volume P. Van Houtte, D. Ball, S. Danhier, and P. Scalliet 21 Radiotherapy and the Challenge of Palliation F. MacBeth and N. Thatcher 22 New Drugs in Cell Lung Cancer J.E. Dancey and F.A. Shepherd 23 Supportive Treatment in the Management of Lunger Cancer L. Crino Subject Index List of Contributors

Blurb

This volume documents the progress that has been made in the treatment of lung cancer, examining in detail the applicability and use of the various therapeutic modalities. Emphasis is placed on the benefits of a multimodality approach to lung cancer, and the editors have sought to achieve a balance between the perspectives offered by US and European authors. The comprehensive coverage of the subject and the expertise of the authors ensure that the volume will be of widest interest.